(HHT) |
| 0 (0%) 10-09 22:52 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 1.18 |
| Resistance 1: | 1.01 |
| Pivot price: | 0.80 |
| Support 1: | 0.69 |
| Support 2: | 0.50 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Wed, 08 Oct 2025
A Case Report of Pulmonary Arterial Hypertension Associated With Hereditary Hemorrhagic Telangiectasia Successfully Treated With Riociguat - Cureus
Fri, 03 Oct 2025
The Swantek Family & HHT Team at CHOP Benefit | Wilkes-Barre, PA | NEPA Events - DiscoverNEPA
Wed, 06 Aug 2025
(PDF) Severe open angle glaucoma in hereditary hemorrhagic telangiectasia - researchgate.net
Fri, 18 Jul 2025
Overlapping upstream ORFs ending at c.125 lead to reduced Endoglin, contributing to Hereditary Hemorrhagic Telangiectasia | Communications Biology - Nature
Wed, 16 Jul 2025
The effect of the COVID-19 pandemic on epistaxis and anaemia in patients with hereditary haemorrhagic telangiectasia (HHT) in central South Africa - Orphanet Journal of Rare Diseases
Sat, 21 Jun 2025
FDA Grants Orphan Drug Designation to DIAG723 for Treatment of HHT - HCPLive
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
